title: [Polycystic ovary syndrome].
abstract: Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by chronic unovulation, hyperandrogenism and polycystic change in ovary. Hyperinsulinemia is so often accompanied with PCOS that insulin resistance may play important roles in pathogenesis of PCOS. Recent studies reported the effectiveness of insulin-sensitizing drugs on treatment of patients with PCOS. Thiazolidinedione, an agonist of PPARgamma receptor, improves not only insulin sensitivity but also hyperandrogenism and ovulatory dysfunction in patients with PCOS. Insulin-sensitizing drugs such as thiazolidinediones are expected to be a novel therapy for PCOS, although further studies on the effectiveness and safety should be required.
authors.affiliation: Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University.
authors.forename: Keizo
authors.initials: K
authors.lastname: Ohnaka
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Takayanagi
mesh_terms: D005260:Female; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D047495:PPAR gamma / Q000819:agonists*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D047495:PPAR gamma; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione